Competitive binding to plasma thyroid hormone transport proteins and thyroid disruption by phenylbutazone used as a probe

General and Comparative Endocrinology

Volumn 174, Issue 2, 2011, Pages 225-231

  Gayrard, Véronique ^a,b   Picard Hagen, Nicole ^a,b   Viguié, Catherine ^a,b   Toutain, Pierre Louis ^a,b  

^a TOXALIM RESEARCH CENTRE IN FOOD TOXICOLOGY   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Competitive binding; Homeostasis; Thyroid hormone

Indexed keywords

LIOTHYRONINE; PHENYLBUTAZONE; PLASMA PROTEIN; THYROID HORMONE; THYROTROPIN; THYROXINE;

ANIMAL EXPERIMENT; ARTICLE; BINDING COMPETITION; BINDING SITE; CONTROLLED STUDY; FEMALE; FREE THYROXINE INDEX; IN VITRO STUDY; IN VIVO STUDY; LIOTHYRONINE BLOOD LEVEL; NONHUMAN; PLASMA CLEARANCE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; SHEEP; THYROID FUNCTION; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

EID: 80054124003     PISSN: 00166480     EISSN: 10956840     Source Type: Journal    
DOI: 10.1016/j.ygcen.2011.09.001     Document Type: Article

References (32)

1. Aylward S.P., Walker T.M., Atterwill C.K. Modulation of thyroxine uptake and efflux in vitro by temelastine and phenobarbital in cultured hepatocytes from different species, in relation to toxicological effects on the thyroid gland. Toxicol. In Vitro 1994, 8:309-316.
2. Benet L.Z., Hoener B.A. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 2002, 71:115-121.
3. Boas M., Feldt-Rasmussen U., Skakkebaek N.E., Main K.M. Environmental chemicals and thyroid function. Eur. J. Endocrinol. 2006, 154:599-611.
4. Cheek A.O., Kow K., Chen J., McLachlan J.A. Potential mechanisms of thyroid disruption in humans: interaction of organochlorine compounds with thyroid receptor, transthyretin, and thyroid-binding globulin. Environ. Health Perspect. 1999, 107:273-278.
5. Chignell C.F., Starkweather D.K. Species differences in the binding of phenylbutazone to plasma albumin. Pharmacology 1971, 5:235-244.
6. Chopra I.J., Sack J., Fisher D.A. 3, 3', 5'-Triiodothyronine (reverse T3) and 3, 3', 5-triiodothyronine (T3) in fetal and adult sheep: studies of metabolic clearance rates, production rates, serum binding, and thyroidal content relative to thyroxine. Endocrinology 1975, 97:1080-1088.
7. J.C. D'Arcy, Pharmacokinetic drug interactions, in: J.C. D'Arcy, J.C. McElnay, P.G. Welling (Eds.), Mechanisms of drug interactions, Springer, Berlin; 1996, pp. 1-9.
8. Dahl G.E., Evans N.P., Thrun L.A., Karsch F.J. A central negative feedback action of thyroid hormones on thyrotropin-releasing hormone secretion. Endocrinology 1994, 135:2392-2397.
9. Davis P.J., Spaulding S.W., Gregerman R.I. The three thyroxine-binding proteins in rat serum: binding capacities and effects of binding inhibitors. Endocrinology 1970, 87:978-986.
10. De Pablo-Davila F., Miralles-García J.M., Hernández-Miguel E., García Iglesias C., Corrales-Hernández J.J., Castro del Pozo S. Study of the kinetics of the thyroid hormones and the peripheral conversion rate of thyroxine to triiodothyronine in acute renal insufficiency under experimental conditions. Horm. Metab. Res. 1980, 12:529-536.
11. Harju M., Hamers T., Kamstra J.H., Sonneveld E., Boon J.P., Tysklind M., Andersson P.L. Quantitative structure-activity relationship modeling on in vitro endocrine effects and metabolic stability involving 26 selected brominated flame retardants. Environ. Toxicol. Chem 2007, 26:816-826.
12. Hennemann G., Docter R., Edith C., Frieseman H., de Jong M., Krenning E.P., Visser T.J. Plasma membrane transport of thyroid hormones and is role in thyroid hormone metabolism and bioavailability. Endocr. Rev. 2001, 22:451-476.
13. Hill R.N., Crisp T.M., Hurley P.M., Rosenthal S.L., Singh D.V. Risk assessment of thyroid follicular cell tumors. Environ. Health Perspect. 1998, 106:447-457.
14. Ishihara A., Sawatsubashi S., Yamauchi K. Endocrine disrupting chemicals: interference of thyroid hormone binding to transthyretins and to thyroid hormone receptors. Mol. Cell Endocrinol. 2003, 199:105-117.
15. Larsson M., Pettersson T., Carlström A. Thyroid hormone binding in serum of 15 vertebrate species: isolation of thyroxine-binding globulin and prealbumin analogs. Gen. Comp. Endocrinol. 1985, 58:360-375.
16. Larsen P.R., Davies T.F., Schlumberger M.J., Hay I.D. Thyroid physiology and diagnostic evaluation of patients with thyroid disorders. Williams Textbook of Endocrinology 2002, 331-373. Saunders, Philadelphia. P.R. Larsen, H.M. Kroneenberg, S. Melmed, K.S. Polonsky (Eds.).
17. Leghait J., Gayrard V., Toutain P.L., Picard-Hagen N., Viguié C. Is the mechanisms of fipronil-induced thyroid disruption specific of the rat: re-evaluation of fipronil thyroid toxicity in sheep?. Toxicol. Lett. 2010, 194:51-57.
18. Lim C.F., Wynne K.N., Barned J.M., Topliss D.J., Stockigt J.R. Non-isotopic spectrophotometric determination of the unbound fraction of drugs in serum. J. Pharm. Pharmacol. 1986, 38:795-800.
19. McElnay J.C. Drug interactions at plasma and tissue binding sites. Mechanisms of Drug Interactions 1996, 1-9. Springer, Berlin. J.C. D'Arcy, J.C. McElnay, P.G. Welling (Eds.).
20. Purkey H.E., Palaninathan S.K., Kent K.C., Smith C., Safe S.H., Sacchettini J.C., Kelly J.W. Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity. Chem. Biol. 2004, 11:1719-1728.
21. Rao G.S., Roa M.L., Thilmann A., Quednau H.D. Studies of fluxes at low concentrations of L-tri-iodothyronine with rat liver cells and their plasma-membrane vesicles. Biochem. J. 1981, 198:457-466.
22. Rolan P.E. Plasma protein binding displacement interactions- why are they still regarded as clinically important. Br. J. Clin. Pharmac. 1994, 37:125-128.
23. Rose J.Q., Yurchak A.M., Jusko W.J. Dose dependent pharmacokinetics of prednisone prednisolone in man. J. Pharmacokinet. Biopharm. 1981, 9:389-417.
24. Rosenthal H.E. A graphic method for the determination and presentation of binding parameters in a complex system. Anal. Biochem 1967, 20:525-532.
25. Rowland M., Tozer T.M. Clinical Pharmacokinetics: Concepts and Applications 1995, Williams and Wilkins, Baltimore. third ed.
26. Samuels M.H., Pillote K., Asher D., Nelson J.C. Variable effects of nonsteroidal antiinflammatory agents on thyroid test results. J. Clin. Endocrinol. Metab. 2003, 88:5710-5716.
27. Sterling K., Brenner M.A. Free thyroxine in human serum: simplified measurement with the aid of magnesium precipitation. J. Clin. Invest. 1966, 45:153-163.
28. Stockigt J.R., Lim C.F. Medications that distort in vitro tests of thyroid function, with particular reference to estimates of serum free thyroxine. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23:753-767.
29. Sutherland R.L., Simpson-Morgan M.W. The thyroxine-binding properties of serum proteins. A competitive binding technique employing sephadex G-25. J. Endocrinol. 1975, 65:319-332.
30. Topliss D.J., Kolliniatis E., Barlow J.W., Lim C.F., Stockigt J.R. Uptake of 3,5,3'-triiodothyronine by cultured rat hepatoma cells is inhibitable by nonbile acid cholephils, diphenylhydantoin, and nonsteroidal antiinflammatory drugs. Endocrinology 1989, 124:980-986.
31. Toutain P.L., Bousquet-Mélou A. Plasma clearance. J. Vet. Pharmacol. Ther. 2004, 37:415-425.
32. Wang R., Nelson J.C., Wilcox R.B. Salsalate administration--a potential pharmacological model of the sick euthyroid syndrome. J. Clin. Endocrinol. Metab. 1998, 83:3095-3099.